BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 24054931)

  • 1. Diagnosis and treatment of late-onset hypogonadism: systematic review and meta-analysis of TRT outcomes.
    Corona G; Rastrelli G; Maggi M
    Best Pract Res Clin Endocrinol Metab; 2013 Aug; 27(4):557-79. PubMed ID: 24054931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EMAS position statement: Testosterone replacement therapy in the aging male‏.
    Dimopoulou C; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; Rees M; van der Schouw YT; Senturk LM; Simonsini T; Stevenson JC; Stute P; Goulis DG
    Maturitas; 2016 Feb; 84():94-9. PubMed ID: 26614257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risks and benefits of late onset hypogonadism treatment: an expert opinion.
    Corona G; Vignozzi L; Sforza A; Maggi M
    World J Mens Health; 2013 Aug; 31(2):103-25. PubMed ID: 24044106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adult- and late-onset male hypogonadism: the clinical practice guidelines of the Italian Society of Andrology and Sexual Medicine (SIAMS) and the Italian Society of Endocrinology (SIE).
    Isidori AM; Aversa A; Calogero A; Ferlin A; Francavilla S; Lanfranco F; Pivonello R; Rochira V; Corona G; Maggi M
    J Endocrinol Invest; 2022 Dec; 45(12):2385-2403. PubMed ID: 36018454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone therapy of men with type 2 diabetes mellitus - a randomized, double-blinded, placebo-controlled study.
    Magnussen LV
    Dan Med J; 2017 Jul; 64(7):. PubMed ID: 28673384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone Replacement Therapy and Components of the Metabolic Syndrome.
    Anaissie J; Roberts NH; Wang P; Yafi FA
    Sex Med Rev; 2017 Apr; 5(2):200-210. PubMed ID: 28202344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome.
    Hackett G
    Sex Med Rev; 2019 Jul; 7(3):476-490. PubMed ID: 30803918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone and metabolic syndrome: a meta-analysis study.
    Corona G; Monami M; Rastrelli G; Aversa A; Tishova Y; Saad F; Lenzi A; Forti G; Mannucci E; Maggi M
    J Sex Med; 2011 Jan; 8(1):272-83. PubMed ID: 20807333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The complex association between metabolic syndrome and male hypogonadism.
    Dimopoulou C; Goulis DG; Corona G; Maggi M
    Metabolism; 2018 Sep; 86():61-68. PubMed ID: 29656047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of testosterone treatment in patients with metabolic disorders.
    Corona G; Rastrelli G; Vignozzi L; Barbonetti A; Sforza A; Mannucci E; Maggi M
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1091-1103. PubMed ID: 34085587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MYTHS AND CONTROVERSIES IN HYPOGONADISM TREATMENT OF AGING MALES.
    Ungureanu MC; Costache II; Preda C; Mogoş V; Vulpoi C; Leuştean L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):325-33. PubMed ID: 26204632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late-onset hypogonadism and lifestyle-related metabolic disorders.
    Braga PC; Pereira SC; Ribeiro JC; Sousa M; Monteiro MP; Oliveira PF; Alves MG
    Andrology; 2020 Nov; 8(6):1530-1538. PubMed ID: 31991053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late-onset hypogonadism: current concepts and controversies of pathogenesis, diagnosis and treatment.
    Huhtaniemi I
    Asian J Androl; 2014; 16(2):192-202. PubMed ID: 24407185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.
    Lapauw B; Kaufman JM
    Eur J Endocrinol; 2020 Dec; 183(6):R167-R183. PubMed ID: 33105105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis.
    Kohn TP; Mata DA; Ramasamy R; Lipshultz LI
    Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients with testosterone deficiency syndrome and type 2 diabetes.
    Corona G; Maggi M
    Arch Esp Urol; 2013 Sep; 66(7):711-22. PubMed ID: 24047631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of testosterone replacement therapy for treating metabolic disturbances in late-onset hypogonadism: a systematic review and meta-analysis.
    Kim SH; Park JJ; Kim KH; Yang HJ; Kim DS; Lee CH; Jeon YS; Shim SR; Kim JH
    Int Urol Nephrol; 2021 Sep; 53(9):1733-1746. PubMed ID: 34089171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone replacement therapy for late-onset hypogonadism: current trends in Korea.
    Ko YH; Kim JJ
    Asian J Androl; 2011 Jul; 13(4):563-8. PubMed ID: 21572448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden.
    Arver S; Luong B; Fraschke A; Ghatnekar O; Stanisic S; Gultyev D; Müller E
    J Sex Med; 2014 Jan; 11(1):262-72. PubMed ID: 23937088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes, and prostate health indicators in elderly hypogonadal men.
    Canguven O; Talib RA; El Ansari W; Yassin DJ; Salman M; Al-Ansari A
    Andrologia; 2017 Dec; 49(10):. PubMed ID: 28295504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.